Edwards Lifesciences Corp Investor Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: David Roman - Goldman Sachs - Analyst : Thank you, Mark, David Roman from Goldman Sachs. Maybe we could start on the [TMTT] side. Clearly a lot of drivers here, but as you put the 2026 guidance into context of the $2 billion in 2030, it starts to put a lot of onus on those outer year periods. So can you just walk us through how you get from what it will roughly be $200 million of incremental growth in 206 to something that needs to be multiples of that and as you look forward.

Question: David Roman - Goldman Sachs - Analyst : Thanks everybody. Wanted to ask on the progress trial first last year I think the this Outlook slides had progress as the TAVR growth driver and it wasn't in this year's slides. I don't know if that was a reason to ask on that. And then how long do you think it'll take if the data is positive for this to impact growth and do you need guidelines to change and you know how much you have in your targets for moderate.

Question: David Roman - Goldman Sachs - Analyst : Moderate was one of the fastest and rolling stead, no.